Why Alkermes spun out an oncology company, whose shares have plummeted


The new company's CEO says operating it separately allows for a more focused approach. Plus, it's no longer competing with the rest of Alkermes, which currently has multiple neuroscience drugs in its pipeline, for money or talent.

Previous Dare to Care gets $700K grant from Anthem Medicare, foundation
Next Small Plates: PBR Cowboy Bar, Flavortown and Evans Farm adding beef, wine, coffee and beer